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a b s t r a c t
Background: Patients with submassive pulmonary embolism (PE) are vulnerable to sudden deterioration, recurrent PE, and progression to pulmonary hypertension and chronic right ventricular (RV) dysfunction. Previous
studies have suggested a clinical beneﬁt of using ultrasound-assisted catheter-directed thrombolysis (USCDT)
to invasively manage patients with submassive PE. However, there is sparse data comparing the clinical outcomes of these patients when treated with USCDT versus anticoagulation (AC) alone. We sought to compare
the outcomes of USCDT versus AC alone in the management of submassive PE.
Methods: 192 consecutive patients who underwent USCDT for submassive PE between January 2013 and February 2019 were identiﬁed. ICD9/ICD10 codes were used to detect 2554 patients diagnosed with PE who did not
undergo thrombolysis. Propensity matching identiﬁed 192 patients with acute PE treated with AC alone. Clinical
outcomes were compared between the two groups. Baseline demographics, laboratory values, and pulmonary
embolism severity index scores were similar between the two cohorts.
Results: There was a signiﬁcant reduction in mean systolic pulmonary artery pressure (sPAP) in the USCDT group
compared to the AC group (Δ11 vs Δ3.9 mmHg, p < 0.001). There was signiﬁcant improvement in proportion of
RV dysfunction in all patients, but the difference was larger in the USCDT group (Δ43.3% vs Δ17.3%, p < 0.001).
Patients who underwent USCDT had lower 30-day (4.3% vs 10.5%, p = 0.03), 90-day (5.5% vs 12.4%, p = 0.03),
and 1-year mortality (6.2% vs 14.2%, p = 0.03).
Conclusions: In patients with acute submassive PE, USCDT was associated with improved 30-day, 90-day, and 1
year mortality as compared to AC alone. USCDT also improved RV function and reduced sPAP to a greater degree
than AC alone. Further studies are needed to verify these results in both short- and long-term outcomes.
© 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Introduction
Acute pulmonary embolism (PE) is the third leading cause of cardiovascular death, accounting for an adjusted mortality rate of 3.5 per
100,000 persons in the USA in 2018 [1]. Approximately 40% of PEs are
⁎ Corresponding author at: Henry Ford Hospital, Division of Cardiology, Department of
Internal Medicine, 2799 W Grand Blvd, K2 Cardiology, Ofﬁce E251, Detroit, MI 48202, USA.
E-mail address: gkoenig1@hfhs.org (G. Koenig).

classiﬁed as submassive, as deﬁned by signs of right ventricular (RV)
strain in the absence of hemodynamic instability, and carry signiﬁcant
morbidity and mortality [2]. Patients with submassive PE are vulnerable
to sudden clinical deterioration, development of recurrent PE, and progression to pulmonary hypertension and chronic RV dysfunction [2,3].
Previous studies have suggested clinical beneﬁt of using ultrasoundassisted catheter-directed thrombolysis (USCDT) to invasively manage
patients with high-risk submassive PE [4–6]. USCDT uses highfrequency (2.2 MHz), low-power (0.5 W per element) ultrasound
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with the capacity to disaggregate ﬁbrin ﬁbers and allow for increased
thrombus permeability for thrombolytic drugs to reach plasminogen receptor sites and dissolve embolic clot. Although it is known that USCDT
reduces thrombus burden, improves RV function, and reduces pulmonary hypertension in the short term, its effects on long-term clinical
outcomes when compared to use of anticoagulation (AC) alone remains
unclear [4–6]. We aimed to determine the short- and long-term clinical
outcomes in a propensity matched analysis of patients with acute
submassive PE who underwent USCDT versus AC alone. We also
aimed to determine whether select patient populations with poor
cardiopulmonary reserve would signiﬁcantly beneﬁt from USCDT compared to AC alone.

breaths per minute, (9) 20 points for temperature < 36 °C, (10) 60
points for altered mental status, and (11) 20 points for oxygen
saturation < 90%. Myocardial infarction was deﬁned as a troponin
level above the 99th percentile along with new electrocardiogram
changes or new wall motion abnormalities on echocardiogram. Acute
kidney injury was deﬁned according to the “Kidney Disease: Improving
Global Outcomes” criteria for creatinine [8]. Electronic health records
were used to manually extract 30-day, 90-day, and 1-year outcomes.
CT scans were independently reviewed by G.M. and S.S. for the presence
of RV strain. Echocardiographic variables were manually extracted and
included RV dysfunction, RV dilatation, tricuspid annular plane systolic
excursion (TAPSE), tricuspid regurgitation jet velocity, inferior vena
cava (IVC) diameter, interventricular septum proﬁle, and systolic pulmonary artery pressure (sPAP). RV dysfunction on echocardiogram
was determined by a cardiologist, in adherence to the American Society
of Echocardiography guidelines [9]. In general, RV dysfunction is deﬁned as fractional area change (FAC) <35%, TAPSE <1.7 cm, pulsed
Doppler S wave <9.5 cm/s, pulsed Doppler myocardial performance
index >0.43, or tissue Doppler myocardial performance index >0.54.
The following parameters were further used to grade RV dysfunction:
RV FAC (mild 25–35%, moderate 18–24%, and severe <17%), and/or
TAPSE (mild-moderate 1.0–1.6 cm, severe <1.0 cm).
The primary endpoints included all-cause mortality, recurrent PEs,
and bleeding at 30 days, 90 days, and 1 year post-therapy. Bleeding severity was classiﬁed using the Global Use of Strategies to Open Occluded
Coronary Arteries (GUSTO) [10] bleeding criteria, where severe is deﬁned as either intracranial hemorrhage or bleeding that causes hemodynamic compromise, moderate is deﬁned as bleeding requiring blood
transfusion but no hemodynamic compromise, and mild as bleeding
that does not meet criteria for either severe or moderate. Secondary
endpoints included changes in sPAP and RV function following therapy.
There was proper ethical oversight, the study was approved by the
Institutional Review Board (IRB# 11289), and informed consent was
waived.
In our institution, patients with acute submassive PE are evaluated by
the multi-disciplinary Pulmonary Embolism Response Team (PERT),
which includes members from interventional cardiology, interventional
radiology, cardiothoracic surgery, vascular surgery, and pulmonary hypertension services. The team is activated if there is evidence of RV strain
by CT, echocardiogram, and/or sPESI score ≥ 1 along with biomarker elevation or syncope. An algorithm developed from the European Society
Guidelines [3] is followed, and those with high-risk submassive PE are
considered for USCDT. Patients who receive USCDT typically undergo
the procedure within 24 h of arrival.
Patients who are chosen for USCDT are then taken to the cardiac
catheterization laboratory or interventional radiology laboratory. Femoral or internal jugular venous access is obtained, and a pigtail catheter is
advanced into the appropriate pulmonary artery using CT ﬁndings to
identify the clot location. Based on the clot location, an EkoSonic catheter (EKOS Corp, Bothell, WA, USA) is placed across the heaviest clot
burden for ultrasound-assisted thrombolysis. Unilateral or bilateral
catheters may be inserted into the pulmonary arteries, depending on
the location and burden of clots. The majority of patients required
bilateral catheters (Videos 1–3). An immediate infusion of 2 mg of tissue
plasminogen activator at a concentration of 10 mg/250 mL 0.9% normal
saline is then administered per catheter, followed by initiation of lytic
infusion at rate of 0.5 mg/h to 1 mg/h for a total dose of 24 mg. The
dose may be adjusted per the operator's discretion in special cases
(obesity, extremity low body weight, etc.). During lytic infusion,
patients receive additional low intensity heparin infusion to maintain
partial thromboplastin time in a range of 40–55 s as part of the treatment protocol. After completion of lytic infusion, the catheters are
removed at bedside and patients are switched to high-intensity unfractionated heparin and then long-term anticoagulation.
The group comparisons were performed using chi-square tests for
non-sparse categorical variables, Fisher exact tests for sparse categorical

Methods
We retrospectively identiﬁed 192 consecutive patients through a
cardiac catheterization database registry who underwent USCDT at
our institution for acute submassive PE from January 2013 until February 2019. Submassive PE was deﬁned as the presence of RV strain in
the absence of hemodynamic instability, with RV strain being deﬁned
as: (1) computed tomography (CT) right ventricle: left ventricle (RV:
LV) ratio ≥ 1; or (2) transthoracic echocardiogram RV hypokinesis, RV
dilatation, and/or intraventricular septal bowing; or (3) simpliﬁed pulmonary embolism severity index (sPESI) ≥1. Patients were further classiﬁed as having high-risk submassive PE if they also had elevation in
biomarkers (B-type natriuretic peptide >90 pg/mL, troponin >99th
percentile) or syncope. We excluded patients with low-risk PE (no imaging or biomarker evidence of RV dysfunction) and those with massive
PE (sustained systolic blood pressure < 90 mmHg for at least 30 min or
requiring vasopressor support). Patients were also excluded if they
were initially treated with systemic thrombolysis or surgical embolectomy that was unsuccessful. In evaluating patients, USCDT was contraindicated in the setting of prior intracranial hemorrhage, ischemic
stroke within the past 6 months, central venous system neoplasm,
major trauma, surgery, or head injury within the past 3 weeks. Our center relied on historical data for risk-assessment and did not routinely
obtain cerebral imaging prior to offering USCDT. Using International
Classiﬁcation of Diseases (ICD) 9 and 10 Revision coding, we identiﬁed
2554 patients diagnosed with PE without an associated ICD code for
thrombolysis during the same time period. The study variables for age,
body mass index, gender, race, hypertension, hypersensitivity lung
disease, diabetes, chronic kidney disease, coronary artery disease, congestive heart failure, smoking, chronic lung disease, pulmonary hypertension, prior deep vein thrombosis, prior pulmonary embolism,
hypercoagulable state, cancer, and recent surgery were used to create
a propensity score for each patient. Then the propensity score was
used to match each USCDT case to a corresponding control (AC alone)
using 1 to 1 matching. In order to identify a good quality matched cohort, we assessed patients dating back to 2013. USCDT was not offered
at our institution prior to 2017, so those patients were treated with AC
alone. Ultimately, there were 192 patients in the USCDT group and
192 patients in the control group. Patients were included if they met
the above criteria, were age > 18 years old, and were hemodynamically
stable.
The epidemiological, clinical, laboratory, and procedural data were
manually extracted from electronic health records. Race was based on
self-identiﬁcation. Comorbid conditions were identiﬁed based on patient problem lists and notes. The PESI score is a risk stratiﬁcation tool
that has been externally validated to determine the mortality and outcome of patients with newly diagnosed PE [7]. The PESI score was
used in the propensity matching and was calculated in the following
manner: (1) one point given per year of age, (2) 10 points for male gender, (3) 30 points for history of cancer, (4) 10 points for history of heart
failure, (5) 10 points for history of chronic lung disease (CLD), (6) 20
points for heart rate ≥ 110 beats per minute (bpm), (7) 30 points for systolic blood pressure < 100 mmHg, (8) 20 points for respiratory rate ≥ 30
2
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as medians. Statistical analyses were considered signiﬁcant if p < 0.05. A
time-to-event analysis was performed using Kaplan-Meier curves,
where signiﬁcance was calculated using the log-rank test.

variables, 2-sample t-tests for normally distributed numerical variables,
and Wilcoxon rank sum tests for non-normally distributed numerical variables. Non-normally distributed numerical variables were summarized

Table 1
Baseline characteristics.

I. Demographics
Age
BMI
Male
Race
Black
White
Other
II. Comorbidities
Hypertension
Hyperlipidemia
Diabetes Mellitus
Chronic Kidney Disease
Coronary Artery Disease
Congestive Heart Failure
Smoking
Chronic Lung Disease
Pulmonary Hypertension
Prior DVT
Prior PE
Hypercoagulable state
Recent Surgery
Cancer
III. Initial vital signs
Systolic blood pressure
Diastolic blood pressure
Heart rate
Respiratory rate
Oxygen saturation
Temperature
Altered mental status
Syncope
PESI score
IV. Initial laboratory values
BNP level
Troponin level
Peak troponin
V. CTPE ﬁndings
RV strain
Intraventricular septum
Normal
Flattened
Bowing
IVC contrast reﬂux
VI. Initial echocardiogram
RV dysfunction
Normal
Mild
Moderate
Severe
TAPSE (cm)
TR Jet velocity (cm/s)
Systolic PAP (mmHg)
IVC diameter
Normal, >50% variation
Dilated, >50% variation
Dilated, <50% variation
Intraventricular septum
Normal
Flattened

All
(N = 384)

USCDT
(N = 192)

Anticoagulation
(N = 192)

p-value

59.3 ± 15.1
34.2 ± 9.7
188 (49.0%)

58.9 ± 14.1
34.9 ± 8.7
93 (48.4%)

59.8 ± 16.1
33.5 ± 10.6
95 (49.5%)

0.55
0.18
0.84

141 (38.6%)
198 (54.2%)
26 (7.1%)

71 (40.3%)
91 (51.7%)
14 (8.0%)

70 (37.0%)
107 (56.6%)
12 (6.3%)

0.61

225 (58.6%)
135 (35.2%)
104 (27.1%)
45 (11.7%)
30 (7.8%)
24 (6.3%)
173 (45.1%)
51 (13.3%)
12 (3.1%)
63 (16.4%)
54 (14.1%)
14 (3.6%)
32 (8.3%)
75 (19.5%)

113 (58.9%)
65 (33.9%)
47 (24.5%)
22 (11.5%)
13 (6.8%)
10 (5.2%)
78 (40.6%)
24 (12.5%)
5 (2.6%)
28 (14.6%)
24 (12.5%)
5 (2.6%)
17 (8.9%)
35 (18.2%)

112 (58.3%)
70 (36.5%)
57 (29.7%)
23 (12.0%)
17 (8.9%)
14 (7.3%)
95 (49.5%)
27 (14.1%)
7 (3.6%)
35 (18.2%)
30 (15.6%)
9 (4.7%)
15 (7.8%)
40 (20.8%)

0.92
0.59
0.25
0.87
0.45
0.40
0.08
0.65
0.56
0.34
0.38
0.28
0.71
0.52

127.8 ± 22.5
77.2 ± 15.1
103.2 ± 18.9
22.6 ± 7.5
Median = 20.0
91.3 ± 7.2
Median = 93.0
36.6 ± 0.7
Median = 36.7
32 (8.4%)
32 (8.6%)
100.8 ± 32.0

128.6 ± 23.6
78.2 ± 15.8
106.6 ± 18.0
22.8 ± 5.6
Median = 22.0
90.9 ± 8.4
Median = 92.0
36.6 ± 0.8
Median = 36.7
10 (5.2%)
21 (11.0%)
101.4 ± 29.4

126.9 ± 21.5
76.3 ± 14.3
99.8 ± 19.1
22.4 ± 9.0
Median = 20.0
91.8 ± 5.9
Median = 93.0
36.7 ± 0.6
Median = 36.7
22 (11.5%)
11 (6.1%)
100.1 ± 34.5

0.47
0.22
<0.001
0.02

336.9 ± 652.6
Median = 162.5
0.5 ± 2.0
Median = 0.1
1.3 ± 4.8
Median = 0.2

319.8 ± 659.9
Median = 165.0
0.5 ± 1.1
Median = 0.2
1.3 ± 4.7
Median = 0.3

357.0 ± 645.7
Median = 149.0
0.6 ± 2.6
Median = 0.1
1.2 ± 4.9
Median = 0.1

0.44

251 (65.4%)

152 (79.2%)

99 (51.6%)

<0.001

151 (45.1%)
121 (36.1%)
63 (18.8%)
198 (51.6%)

46 (26.4%)
77 (44.2%)
51 (29.3%)
123 (64.1%)

105 (61.4%)
44 (25.7%)
22 (12.9%)
75 (39.1%)

<0.001
<0.001
<0.001
<0.001

114 (32.9%)
68 (19.7%)
95 (27.5%)
69 (19.9%)
1.76 ± 0.43
292.9 ± 57.5
43.9 ± 14.1

11 (6.7%)
34 (20.9%)
71 (43.6%)
47 (28.8%)
1.63 ± 0.38
306.1 ± 58.7
48.0 ± 13.9

103 (56.3%)
34 (18.6%)
24 (13.1%)
22 (12.0%)
1.89 ± 0.44
281.3 ± 53.7
40.2 ± 13.3

< 0.001
0.69
< 0.001
< 0.001
<0.001
<0.001
<0.001

156 (53.2%)
73 (24.9%)
64 (21.8%)

48 (34.8%)
36 (26.1%)
54 (39.1%)

108 (69.7%)
37 (23.9%)
10 (6.5%)

<0.001
0.76
<0.001

153 (55.8%)
121 (44.2%)

49 (35.5%)
89 (64.5%)

104 (76.5%)
32 (23.5%)

<0.001
<0.001

0.21
0.17
0.03
0.09
0.70

<0.001
<0.001

USCDT, ultrasound-assisted catheter-directed thrombolysis; BMI, body mass index; DVT, deep venous thromboembolism; PE, pulmonary embolism; PESI, pulmonary embolism severity
score; BNP, brain natriuretic peptide; RV, right ventricle; IVC, inferior vena cava; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; PAP, pulmonary artery
pressure.
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values were not clinically signiﬁcant. Most patients had RV strain present by either CT scan or echocardiography. RV strain was present in
65.4% of all patients via CT and RV dysfunction was present in 67.1% of
all patients on echocardiography. Patients who underwent USCDT
were more likely to have RV strain via CT scan, and more likely to
have moderate or severe RV dysfunction on initial echocardiogram, a
bias towards a potentially higher risk population (Table 1).
The rates of in-hospital death, cardiac arrest, need for mechanical
ventilation, and bleeding were similar between the two cohorts
(Table 2). Patients who underwent USCDT had lower rates of acute
kidney injury (9.9% vs 18.3%, p = 0.02) and lower rates of myocardial infarction (1.0% vs 4.2%, p = 0.06), although the latter was not statistically
signiﬁcant. Rates of bleeding, intracranial hemorrhage, recurrent
venous thromboembolism (VTE), including PE, were similar among
the two groups (Table 2). In those who underwent USCDT, 5.2%
developed access site hematomas and 2.6% developed venous
pseudoaneurysms. The form of AC on discharge was similar between
the two cohorts. In the control group, 46.4% of patients were discharged
on direct oral anticoagulants (DOACs) (n = 44/192 apixaban, 30/192
rivaroxaban, 15/192 other), 37.0% on warfarin, and 16.7% on lovenox.
In the intervention group, 46.4% of patients were discharged on
DOACs (n = 53/192 apixaban, 28/192 rivaroxaban, 8/192 other),
44.3% on warfarin, and 9.4% on lovenox. Patients who were placed on
warfarin were bridged using heparin infusion or lovenox injection,
were kept in the therapeutic range by our pharmacists, and followed
up at an international normalized ratio (INR) clinic for regular checks.
Regarding longer term outcomes, patients who underwent USCDT
had lower rates of 30-day mortality (4.3% vs 10.5%, p = 0.03), 90-day
mortality (5.5% vs 12.4%, p = 0.03), and 1-year mortality (6.2% vs 14.2%,
p = 0.03) as compared to AC alone (Fig. 1). Survival analysis using
Kaplan-Meier log-rank test demonstrated signiﬁcant mortality difference
between the two cohorts, favoring USCDT-treated patients (Fig. 2).
Univariate and multivariate subgroup analysis showed no difference
in survival based on underlying comorbidities in those who received
USCDT versus AC only. Patients who underwent USCDT had higher
mean sPAP on initial echocardiogram (48.0 + 13.9 vs 40.2 + 13.3,
p < 0.001), and more signiﬁcant improvement in sPAP on followup echocardiogram done three to six months post-hospitalization
(37 + 12.4 vs 36.3 + 11.7) (Fig. 3). There was signiﬁcant improvement in proportion of RV dysfunction after both USCDT and AC, but
the difference was larger in the group that received USCDT (Fig. 4).
In a subgroup analysis of patients with poor cardiopulmonary reserve, there was no predictor of increased beneﬁt with USCDT as
compared to AC alone (Table 3).
In patients who underwent USCDT, there were a few notable differences about racial and sex differences in outcomes. Despite being similar in age and PESI scores and receiving USCDT, females had higher rates
of RV dysfunction on follow-up echocardiogram. Death, bleeding, and
recurrent VTE rates were similar among males and females (Online
Table 1). Whites had a signiﬁcantly higher survival rate at 30 days as
compared to non-Whites (100% vs 91.8%, p = 0.03), although this difference was not sustained at 90-day or 1-year follow up (Online
Table 2).

Results
A total of 384 patients with acute submassive PE were included in
this study: 192 patients underwent USCDT and 192 propensitymatched patients received AC alone. The mean age for the entire cohort
was 59.3 ± 15.1 years old, 49.0% were male, 54.2% were White, and
38.6% were Black. There were no differences in age, gender, race, comorbidities, or PESI score between the two cohorts (Table 1). Patients who
underwent USCDT had higher initial heart rate, respiratory rate, initial
troponin level, and peak troponin level, although the differences in
Table 2
Outcomes.

I. In-hospital outcomes
In-hospital death
Length of stay

Intracranial
hemorrhage
Cardiac arrest
Ventricular
arrhythmia
Myocardial infarction
Stroke
Acute kidney injury
Intubation/ventilation
Inotropic support
Bleeding
Access site hematoma
Pseudoaneurysm
IVC ﬁlter placed
II. 30-day outcomes
Death
Intracranial
hemorrhage
Bleeding
Recurrent VTE
III. 90-day outcomes
Death
Intracranial
hemorrhage
Bleeding
Recurrent VTE
IV. 1-year outcomes
Death
Intracranial
hemorrhage
Bleeding
Recurrent VTE
V. Follow up
echocardiogram
RV dysfunction
Normal
Mild
Moderate
Severe
TAPSE (cm)
TR jet velocity (cm/s)
Systolic PAP (mmHg)
IVC diameter
Normal, >50%
variation
Dilated, >50%
variation
Dilated, <50%
variation
Intraventricular
septum
Normal
Flattened

All
(N = 384)

USCDT
(N = 192)

Anticoagulation p-value
(N = 192)

14 (3.7%)
7.6 ± 6.9
Median =
5.0
2 (0.5%)

5 (2.6%)
6.9 ± 5.4
Median =
5.0
0 (0.0%)

9 (4.7%)
8.3 ± 8.1
Median = 5.0

0.27
0.64

2 (1.1%)

0.23

6 (1.6%)
6 (1.6%)

3 (1.6%)
3 (1.6%)

3 (1.6%)
3 (1.6%)

1.00
1.00

10 (2.6%)
3 (0.8%)
54 (14.1%)
19 (5.0%)
8 (2.1%)
34 (8.9%)
10 (3.0%)
5 (1.5%)
36 (9.4%)

2 (1.0%)
1 (0.5%)
19 (9.9%)
9 (4.7%)
4 (2.1%)
19 (9.9%)
10 (5.2%)
5 (2.6%)
16 (8.3%)

8 (4.2%)
2 (1.0%)
35 (18.3%)
10 (5.2%)
4 (2.1%)
15 (7.9%)
0 (0.0%)
0 (0.0%)
20 (10.5%)

0.06
0.62
0.02
0.81
1.00
0.48
0.006
0.08
0.47

27 (7.6%)
2 (0.6%)

7 (4.3%)
1 (0.6%)

20 (10.5%)
1 (0.6%)

0.03
1.00

14 (4.1%)
8 (2.3%)

6 (3.7%)
3 (1.8%)

8 (4.4%)
5 (2.8%)

0.74
0.73

30 (9.3%)
0 (0.0%)

8 (5.5%)
0 (0.0%)

22 (12.4%)
0 (0.0%)

0.03
–

13 (4.4%)
10 (3.4%)

8 (5.7%)
7 (5.0%)

5 (3.3%)
3 (2.0%)

0.32
0.20

32 (10.7%)
0 (0.0%)

8 (6.2%)
0 (0.0%)

24 (14.2%)
0 (0.0%)

0.03
–

17 (6.2%)
5 (1.8%)

6 (4.8%)
3 (2.4%)

11 (7.2%)
2 (1.3%)

0.41
0.67

134 (57.3%)
46 (19.7%)
50 (21.4%)
4 (1.7%)
2.16 ± 1.9
271.6 ± 51.5
36.8 ± 12.2

81 (50.0%)
37 (22.8%)
41 (25.3%)
3 (1.9%)
2.20 ± 2.2
274.0 ± 54.3
37.0 ± 12.4

53 (73.6%)
9 (12.5%)
9 (12.5%)
1 (1.4%)
2.95 ± 0.47
266.3 ± 44.3
36.3 ± 11.7

0.001
0.10
0.042
0.80
<0.001
0.13
0.57

163 (78.4%)

119 (78.3%)

44 (78.6%)

0.97

31 (14.9%)

19 (12.5%)

12 (21.4%)

0.17

14 (6.7%)

14 (9.2%)

0 (0.0%)

0.04

169 (85.8%)
28 (14.2%)

130 (89.0%)
16 (11.0%)

39 (76.5%)
12 (23.5%)

0.048
0.048

Discussion
In this retrospective, propensity matched study, patients who underwent USCDT for submassive PE had better long-term clinical and hemodynamic outcomes as compared to those who received AC alone.
This was an overall sick cohort, with an average PESI score of 101
(Class III) and 47.4% of patients having moderate or severe RV dysfunction on presentation. Patients who underwent USCDT had higher initial
sPAP and worse RV dysfunction, but better mortality rates on follow up.
To our knowledge, this is the largest observational study of patients
treated in routine clinical practice (“real world”) evaluating outcomes
of USCDT for submassive PE as compared to AC alone.

USCDT, ultrasound-assisted catheter-directed thrombolysis; IVC, inferior vena cava; VTE,
venous thromboembolism; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; PAP, pulmonary artery pressure.
4

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on June 27, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

S. Gorgis, S. Mawri, M.F. Dabbagh et al.

Journal of Cardiology xxx (xxxx) xxx

Fig. 1. Mortality at different time intervals in USCDT vs AC alone. Patients who underwent USCDT had lower rates of 30-day mortality (4.3% vs 10.5%, p = 0.03), 90-day mortality (5.5% vs
12.4%, p = 0.03), and 1-year mortality (6.2% vs 14.2%, p = 0.03) as compared to AC alone.
AC, anticoagulation; USCDT, ultrasound-assisted catheter-directed thrombolysis.

impact on mortality, with limited long-term outcome data in patients
with submassive PE who undergo USCDT. Only two studies compared
mortality in patients who undergo USCDT versus AC alone. In ULTIMA
(Ultrasound Accelerated Thrombolysis of Pulmonary Embolism), a
total of only 59 patients were randomized to USCDT versus AC alone,
and there was no statistical difference in 90-day mortality between
the two small cohorts [4]. Avgerions et al. had the largest retrospective
analysis, evaluating 128 patients who underwent either CDT or AC alone
for submassive PE, and found no difference in 90-day all-cause mortality
or major adverse events between the two groups [13]. In this current
study of 394 patients, we show that there is a sustained improvement
in survival at 30 days, 90 days, and 1 year in patients who received
USCDT. A notable difference between our study and that of Avgerions
et al.'s is the matching of baseline characteristics. The rate of recurrent

The previously reported short- and long-term survival in patients
with submassive PE is sparse and limited [11]{Alotaibi, 2018 #11}.
Anticoagulation has been the standard treatment, aimed to slow thrombus progression in the early phase and to reduce thrombus recurrence
in the long term. Although early recognition and treatment has improved short-term outcomes, it is estimated that 5-year mortality
post-PE is still about 25% [12]. Systemic thrombolytics can achieve faster
pulmonary reperfusion, but this treatment is reserved for those with
hemodynamic compromise given the signiﬁcantly increased risk of
bleeding, particularly intracranial hemorrhage. USCDT was introduced
as a method to deliver thrombolytic therapy directly into the pulmonary
circulation, thus lowering the systemic bleeding risk. The major aim was
to reduce pulmonary thrombus burden and subsequent hemodynamic
consequences that lead to RV dysfunction. Unknown is the speciﬁc

Fig. 2. Survival analysis using Kaplan-Meier log-rank test demonstrated signiﬁcant mortality difference between the two cohorts, favoring USCDT-treated patients.
AC, anticoagulation; USCDT, ultrasound-assisted catheter-directed thrombolysis.
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Fig. 3. Changes in systolic pulmonary arterial pressure in USCDT vs AC alone. Patients who underwent USCDT had higher mean sPAP on initial echocardiogram (48.0 + 13.9 vs 40.2 + 13.3
mmHg, p < 0.001), and more signiﬁcant improvement in sPAP on follow-up echocardiogram done three to six months post-hospitalization (37 + 12.4 vs 36.3 + 11.7 mmHg).
AC, anticoagulation; sPAP, systolic pulmonary artery pressure; USCDT, ultrasound-assisted catheter-directed thrombolysis.

VTE was signiﬁcantly higher in Avgerions et al.'s CDT cohort, which may
suggest a more vulnerable patient group. To ultimately address this
question on a large scale, the HI-PEITHO study has been approved to

randomize patients with submassive PE to USCDT or AC alone, but is
still in its early phase of recruiting centers (ClinicalTrials.gov ID:
NCT04790370).

Fig. 4. Changes in right ventricular function in USCDT vs AC alone. There was signiﬁcant improvement in proportion of right ventricular dysfunction after both USCDT and AC, but the difference was larger in the group that received USCDT.
AC, anticoagulation; USCDT, ultrasound-assisted catheter-directed thrombolysis.
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targeted for intervention. Prior studies have also reported similar ﬁndings
[4,5]. ULTIMA demonstrated a signiﬁcant decrease in sPAP (Δ12.3 ± 10.0
mmHg, p < 0.001), diastolic (Δ3.2 ± 7.8 mmHg, p = 0.049), and mean
pulmonary artery pressures (Δ5.7 ± 7.6 mmHg, p < 0.001) at 18 h after
initiation of USCDT; and SEATTLE II reported an absolute difference of
−14.4 ± 15.4 mmHg in sPAP following USCDT [5].
There were a few notable differences in outcomes based on race
and sex in patients who underwent USCDT. Whites had a signiﬁcantly higher 30-day survival rate as compared to non-Whites, although this difference was not noted on longer follow up. The
reason for this ﬁnding is unclear, but may be related to social determinants of health and access to early follow up. The survival difference based on race in patients presenting with acute PE has been
evaluated in several large studies, with Whites universally having
improved early survival [23–25]. In our study, this racial survival difference was also noted in patients who receive USCDT. There are limited data on sex differences in patients with acute PE, but one study
of 1428 patients did demonstrate that severe cases with massive embolism were more commonly seen in women compared to men
(14.6% vs 9.2%, p < 0.001) and 30-day PE-related mortality was signiﬁcantly higher in women than men (5% vs 2.8%, p = 0.04) [26].
In our analysis, there was no difference in mortality based on sex in
those who underwent USCDT, but rather RV function. Females had
higher rates of RV dysfunction on follow-up echocardiogram, despite
being similar in age, PESI score, and receiving USCDT. This may suggest that females are more susceptible to long-term adverse RV consequences, for unclear reasons. Finally, we hypothesized that USCDT
may provide more beneﬁt to patients with increased risk factors for
CTEPH, particularly those with underlying CLD or CHF. However,
our subgroup analysis did not identify any increased beneﬁt of
USCDT in patients with any underlying comorbidity, but we may
have been limited by small numbers.
There is sparse direct comparison of USCDT versus AC alone in
submassive PE. In our propensity matched analysis of 394 patients, we
show that those who underwent USCDT had improved reduction in
sPAP, RV dysfunction, and mortality rates as compared to the use of
AC alone.

Table 3
Univariable log-rank test results for 1-year mortality.
Predictor

p-value

Hypertension
Smoking
Diabetes
CAD
CHF
CLD
PH
Prior DVT
Prior PE

0.383
0.316
0.740
0.930
0.316
0.188
0.243
0.478
0.444

CAD, coronary artery disease; CHF, congestive heart failure; CLD, chronic lung disease; PH, pulmonary hypertension; DVT, deep venous thrombosis; PE, pulmonary
embolism.

RV dysfunction following acute PE can lead to hemodynamic collapse and death. This is clinically recognized as sustained hypotension
in those with massive PE. The systemic consequences of PE lay on a
spectrum of hemodynamic sequela, and submassive PE serves as a potential precursor of hemodynamic compromise with biomarker and/or
imaging evidence of RV strain. Despite being deﬁned as hemodynamically stable, patients with submassive PE carry a 5–25% mortality rate
[14]. The RV, being a thin-walled chamber, is accustomed to contracting
against a highly compliant, low-pressure system (pulmonary arteries
and arterioles). In submassive PE, the RV compensates until the pressure in the pulmonary vasculature typically exceeds 40 mmHg [14]. Pulmonary artery pressures rise from the resistance caused by obstructing
emboli and vasoconstriction caused by hypoxia. Following Laplace's
law, the RV dilates causing under ﬁlling, resulting in the coronary arteries becoming underperfused, and development of RV ischemia [15]. The
ischemic RV develops worse contractility leading to RV dilatation, reduced LV output, and cardiogenic shock [16]. Therefore, intervention
that reduces pulmonary artery pressures and RV dilatation early may
prevent adverse RV remodeling. USCDT has been shown to be effective
in timely reduction of sPAP and improving RV function in patients with
submassive PE. In our cohort, severe RV dysfunction was reduced from
28.8% to 1.9%, and moderate dysfunction was reduced from 43.6% to
25.3% in those who received USCDT (Fig. 4). This is further supported
by reduced rates of intraventricular septal ﬂattening (64.5% vs 11.0%)
and dilated IVC diameters (65.1% vs 21.7%) following USCDT treatment.
This is consistent with data from ULTIMA [4], SEATTLE II [5], and
PERFECT [6]. There was also improvement in rates of RV dysfunction
in patients who received AC alone, but the degree of improvement
was signiﬁcantly less than in the USCDT group (Fig. 4).
The development of chronic thromboembolic pulmonary hypertension (CTEPH) in patients with PE has signiﬁcant consequences. CTEPH
arises from pulmonary emboli that do not resolve and lead to chronic
obstruction of the pulmonary vasculature with subsequent high pulmonary vascular resistance [17]. It is estimated to occur in 2–4% of patients
with acute PE [18,19]. When left untreated, it carries a poor prognosis,
with limited therapeutic options of surgical embolectomy through pulmonary endarterectomy and percutaneous balloon pulmonary angioplasty [20,21]. Factors known to increase risk of development of
CTEPH include recurrent unprovoked PE, large perfusion defects, initial
sPAP >50 mmHg, and persistent pulmonary hypertension on echocardiogram performed 6 months after PE is detected [22]. Increased awareness of the burden of CTEPH has resulted in the creation of PERT teams
that aim to identify high-risk submassive PE patients and offer early
invasive treatment. In our study, patients who underwent USCDT or
AC-alone both had a signiﬁcant reduction in their follow-up sPAP. However, patients who underwent USCDT had higher initial sPAP (48.0 ±
13.9 vs 40.2 ± 13.3 mmHg, p < 0.001) and a more signiﬁcant reduction
in sPAP on follow up (Δ11.0 vs 3.9 mmHg, p < 0.001). This is expected, as
patients with increased risk for long-term consequences are those

Limitations
Despite several strengths of this study, there are notable limitations.
This is a single center retrospective study, which relies on previously
documented information to be reliably present on presentation. Although propensity matching was performed for baseline characteristics
and presenting PESI scores, patients who underwent USCDT did appear
to have higher rates of RV dysfunction and sPAP on initial echocardiogram.
Conclusions
In patients with acute submassive PE, USCDT may be associated with
improved 30-day, 90-day, and 1-year mortality as compared to AC
alone. USCDT also improves RV function and reduces sPAP to a greater
degree than AC alone. Large randomized prospective trials are needed
to conﬁrm these ﬁndings.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.jjcc.2022.04.008.
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